2024
A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
Poppe M, Le-Rademacher J, Haffty B, Hansen E, Agarwal J, Wagner J, Kong I, Armer J, Arthur D, Whelan T, Lee M, Kour O, Lustberg M, Partridge A, Carey L, Ruddy K, Gaffney D, Stecklein S, Bernstein M, Khan A. A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s11. DOI: 10.1016/j.ijrobp.2024.07.002.Peer-Reviewed Original ResearchPost-mastectomy radiation therapyNeoadjuvant chemotherapyBreast reconstructionComplication rateReconstruction complicationsBreast cancerNon-inferiorityHigh-risk breast cancerBody mass index >Conventionally fractionated radiationGenetic predisposition genesImplant-only reconstructionsMedian Follow-UpImmediate breast reconstructionOne-sided type I errorNon-inferiority marginStandard of careHypofractionated radiationRegional recurrenceRadiation therapyTumor characteristicsInvasive BCAdjuvant chemotherapyPredisposition genesMedian ageA Novel Approach for Conducting a Catchment Area Analysis of Breast Cancer by Age and Stage for a Community Cancer Center.
Siegel S, Zhang Y, Lynch S, Rowland J, Curriero F. A Novel Approach for Conducting a Catchment Area Analysis of Breast Cancer by Age and Stage for a Community Cancer Center. Cancer Epidemiology Biomarkers & Prevention 2024, 33: 646-653. PMID: 38451180, PMCID: PMC11062816, DOI: 10.1158/1055-9965.epi-23-1125.Peer-Reviewed Original ResearchRacial disparitiesCancer center catchment areasU.S. Preventive Services Task ForceBreast cancerPreventive Services Task ForceBlack womenCancer registry dataCenter catchment areasStandardized incidence ratioCommunity cancer centerInitial breast cancerBurden of BCCatchment areaInvasive BCBC mortalityIncidence ratiosYoung Black womenIdentified geographic areasCommunity outreachRate of BCAnalysis of breast cancerRegistry dataBC communitiesOverall burdenCancer Center
2021
The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant
Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, Borg A, Caldés T, Caligo MA, Chung WK, Claes KBM, Collaborators G, Barouk-Simonet E, Belotti M, Berthet P, Bignon Y, Bonadona V, Paillerets B, Buecher B, Caputo S, Caron O, Castera L, Caux-Moncoutier V, Colas C, Collonge-Rame M, Coupier I, de Pauw A, Delnatte C, Elan C, Faivre L, Ferrer S, Gauthier-Villars M, Gesta P, Giraud S, Golmard L, Houdayer C, Lasset C, Laurent M, Leroux D, Longy M, Mari V, Mazoyer S, Mebirouk N, Mortemousque I, Prieur F, Pujol P, Saule C, Schuster H, Sevenet N, Sobol H, Sokolowska J, Venat-Bouvet L, Collaborators E, Ahmed M, Barwell J, Brady A, Brennan P, Brewer C, Cook J, Davidson R, Donaldson A, Dunning A, Eason J, Eccles D, Gregory H, Hanson H, Harrington P, Henderson A, Hodgson S, Kennedy M, Lalloo F, Miller C, Morrison P, Ong K, O’Shaughnessy-Kirwan A, Perkins J, Porteous M, Rogers M, Side L, Snape K, Walker L, Collée J, Couch F, Daly M, Dennis J, Dhawan M, Domchek S, Eeles R, Engel C, Evans D, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz P, Garber J, Gayther S, Gerdes A, Godwin A, Goldgar D, Hahnen E, Hake C, Hamann U, Hogervorst F, Hooning M, Hopper J, Hulick P, Imyanitov E, Investigators O, Glendon G, Mulligan A, Investigators H, van Asperen C, Aalfs C, Adank M, Ausems M, Blok M, Garcia E, Heemskerk-Gerritsen B, Hollestelle A, Jager A, Koppert L, Koudijs M, Kriege M, Meijers-Heijboer H, Mensenkamp A, Mooij T, Oosterwijk J, van den Ouweland A, van der Baan F, van der Hout A, van der Kolk L, van der Luijt R, van Deurzen C, van Doorn H, van Engelen K, van Hest L, van Os T, Verhoef S, Vogel M, Wijnen J, Investigators K, Beesley J, Fox S, Holland H, Phillips K, Spurdle A, Isaacs C, Izatt L, Jakubowska A, James P, Janavicius R, Jensen U, Jiao Y, John E, Joseph V, Karlan B, Kets C, Konstantopoulou I, Kwong A, Legrand C, Leslie G, Lesueur F, Loud J, Lubiński J, Manoukian S, McGuffog L, Miller A, Gomes D, Montagna M, Mouret-Fourme E, Nathanson K, Neuhausen S, Nevanlinna H, Yie J, Olah E, Olopade O, Park S, Parsons M, Peterlongo P, Piedmonte M, Radice P, Rantala J, Rennert G, Risch H, Schmutzler R, Sharma P, Simard J, Singer C, Stadler Z, Stoppa-Lyonnet D, Sutter C, Tan Y, Teixeira M, Teo S, Teulé A, Thomassen M, Thull D, Tischkowitz M, Toland A, Tung N, van Rensburg E, Vega A, Wappenschmidt B, Devilee P, Bernstein J, Offit K, Easton D, Rookus M, Chenevix-Trench G, Antoniou A, Robson M, Schmidt M. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics In Medicine 2021, 23: 1726-1737. PMID: 34113011, PMCID: PMC8460445, DOI: 10.1038/s41436-021-01198-7.Peer-Reviewed Original ResearchConceptsCBC riskHazard ratioFirst BCC-indexPolygenic risk scoresRisk scoreConfidence intervalsContralateral breast cancer riskBreast cancer polygenic risk scoreBRCA2 pathogenic variantsAge 40 yearsBreast cancer riskMultifactorial risk modelEuropean ancestryModifiers of BRCA1/2Breast cancer risk predictionCancer risk predictionConsortium of InvestigatorsRetrospective seriesInvasive BCPathological characteristicsFamily historyEstrogen receptorHeterozygous BRCA1Cancer risk
2019
A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer
Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters 2019, 19: 476-486. PMID: 31897161, PMCID: PMC6924059, DOI: 10.3892/ol.2019.11123.Peer-Reviewed Original ResearchNon-muscle invasive BCMuscle-invasive BCIndependent prognostic biomarkerInvasive BCPrognostic biomarkerProlonged recurrence-free survivalCancer-specific survivalCancer-specific deathRecurrence-free survivalTissues of patientsBC tissue samplesExpression of mRNAVital clinical significanceMIBC patientsBC prognosisPoor prognosisBladder cancerClinical significanceCancer tumorigenesisUseful markerLow expressionPatientsNovel tumorHigh expressionTissue samples
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply